Leadless Pacemakers: 10 Years of Cleveland Clinic Experience and the Future of Cardiac Pacing
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of EP Lab Digest or HMP Global, their employees, and affiliates.
EP LAB DIGEST. 2026;26(11).
Interview by Jodie Elrod
In this interview, EP Lab Digest speaks with Mohammad Mdaihly, MD, about his presentation, “Leadless Pacemakers in Clinical Practice: A Decade of Experience," at the 2026 American Heart Association (AHA) Scientific Sessions.
Please introduce yourself and briefly describe your clinical and research focus at Emory.
My name is Mohamad Mdaihly, and I’m currently an internal medicine resident at Emory University. Before joining Emory, I completed a postdoctoral research fellowship in cardiac electrophysiology (EP) at the Cleveland Clinic main campus. During my fellowship, my research spanned both translational and clinical EP.
On the translational side, I worked on preclinical porcine studies investigating catheter ablation technologies, particularly pulsed field ablation. Our work explored how catheter design, energy delivery modalities, and procedural factors influence lesion formation and safety, as well as potential interactions between ablation systems and cardiac implantable electronic devices (CIEDs).
Complementing this work, my clinical research involves large registries examining atrial fibrillation ablation, CIEDs, and transvenous lead extraction. I developed a particular interest in leadless pacemakers, focusing on their real-world safety, procedural outcomes, and evolving role in clinical practice.
What did you discuss in your AHA presentation about the evolution of leadless pacemakers and the lessons learned from a decade of clinical experience?
Leadless pacing has evolved substantially over the past decade. Early devices were limited to single-chamber ventricular pacing, restricting their use to a relatively small subset of patients requiring permanent pacing. The introduction of Micra AV (Medtronic) in 2020 represented a major advancement, enabling atrioventricular (AV) synchronous ventricular pacing. More recently, the Aveir DR (Abbott) became the first dual-chamber leadless pacing system to be approved by the US Food and Drug Administration, enabling both atrial and ventricular sensing and pacing. Together, these advances have significantly expanded the range of patients who may benefit from leadless pacing.
Building on these technological advances, we're presenting our 10-year experience with leadless cardiac device implantation at the Cleveland Clinic, from 2015 through 2025. Our study included 570 patients who underwent 685 implantation procedures, encompassing multiple generations of leadless technology, from early single-chamber ventricular devices to newer AV synchronous and dual-chamber systems, as well as emerging leadless pacing technologies.
We focused on procedural success, technical challenges, and complications across these different platforms. One of our most important findings was the high procedural success rate of 99.4%, which was consistent across manufacturers. We also observed a relatively low procedural complication rate of 2.8%, including cardiac perforation or tamponade, device dislodgement or embolization, and other less frequent adverse events. Technical difficulties were encountered in only 3.3% of procedures, most commonly related to challenging cardiac anatomy.
I think the key takeaway from our experience is that leadless device implantation can be performed with very high procedural success rates across different platforms, even as the technology continues to evolve. At the same time, our findings remind us that these procedures are not without risks, and that careful patient selection, attention to anatomical challenges, and procedural expertise remain important for achieving optimal outcomes.
What key take-home messages about the current role and future of leadless pacing would you like viewers to remember?
I think there are 3 important take-home messages.
First, leadless pacing is no longer simply an alternative for patients who cannot receive conventional transvenous pacemakers. It has become an increasingly important option in contemporary cardiac pacing, particularly for patients at increased risk of device infection, those with limited venous access, or those in whom avoiding transvenous leads is especially beneficial.
Second, our 10-year experience demonstrates that leadless device implantation can be performed with excellent procedural success and a low complication rate. However, it's important to remember that these procedures are not entirely risk-free, and complications such as cardiac perforation, although uncommon, can be serious.
Finally, I think the future of leadless pacing is particularly exciting. We've already seen the transition from single-chamber to dual-chamber leadless pacing, and newer developments in leadless cardiac resynchronization therapy, conduction system pacing, and communication between implanted devices are opening the door to even more advanced pacing strategies. I think we're moving toward a future where leadless technology can address increasingly complex pacing needs and offer more patients an alternative to conventional transvenous systems.
Ultimately, the goal is not necessarily to replace every conventional pacemaker, but to identify the right pacing technology for the right patient.
The transcripts were edited for clarity and length.



